【レポートの概要（一部）】
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 9
1.2 List of Figures 10
2 Introduction 12
2.1 What Is This Report About? 12
3 Definitions of Markets/Categories Covered 13
3.1 Wound Care Management 13
3.1.1 Advanced Wound Management 13
3.1.2 Ostomy Drainage Bags 13
4 Company Snapshot 14
4.1 Key Information 14
4.2 Company Overview 14
4.3 SWOT Snapshot 14
4.4 Business Overview 15
4.5 Major Products and Services 16
4.5.1 Overview 16
5 History 17
6 SWOT Analysis 20
6.1 Overview 20
6.2 ConvaTec Inc. Strengths 20
6.2.1 Geographical Diversity 20
6.2.2 Extensive Product Assortment 21
6.2.3 Awards and Recognitions 21
6.3 ConvaTec Inc. Weaknesses 21
6.3.1 Product Recalls 21
6.3.2 Dependence on Limited Number of Suppliers 22
6.4 ConvaTec Inc. Opportunities 22
6.4.1 Global Wound Care Management Market 22
6.4.2 Strategic Acquisitions 22
6.4.3 Perpetual Innovation 22
6.5 ConvaTec Inc. Threats 23
6.5.1 Stringent Regulatory Environment 23
6.5.2 Cost Containment Pressures 23
6.5.3 Rapid Technological Changes 23
7 Competitors 24
8 Competitive Landscape 25
8.1 Wound Care Management (Advanced Wound Management), Global, Market Share (%), 2011 25
8.2 ConvaTec Inc., Wound Care Management (Advanced Wound Management), by Region, Market Share (2011) 27
8.3 ConvaTec Inc., Wound Care Management (Advanced Wound Management), by Country, Market Share (2011) 28
8.4 Wound Care Management (Ostomy Drainage Bags), Global, Market Share (%), 2011 30
8.5 ConvaTec Inc., Wound Care Management (Ostomy Drainage Bags), by Region, Market Share (2011) 31
8.6 ConvaTec Inc., Wound Care Management (Ostomy Drainage Bags), by Country, Market Share (2011) 32
9 ConvaTec Inc Medical Equipment Market Share Analysis by Category 34
9.1 ConvaTec Inc., Wound Care Management, Global, Category Revenue Share (2011) 34
9.2 ConvaTec Inc., Asia-Pacific, Category Revenue Share (2011) 36
9.2.1 ConvaTec Inc., Australia, Category Revenue Share (2011) 38
9.2.2 ConvaTec Inc., China, Category Revenue Share (2011) 40
9.2.3 ConvaTec Inc., India, Category Revenue Share (2011) 42
9.2.4 ConvaTec Inc., Japan, Category Revenue Share (2011) 44
9.2.5 ConvaTec Inc., Other Asia-Pacific, Category Revenue Share (2011) 46
9.3 ConvaTec Inc., Europe, Category Revenue Share (2011) 48
9.3.1 ConvaTec Inc., France, Category Revenue Share (2011) 50
9.3.2 ConvaTec Inc., Germany, Category Revenue Share (2011) 52
9.3.3 ConvaTec Inc., Italy, Category Revenue Share (2011) 54
9.3.4 ConvaTec Inc., Spain, Category Revenue Share (2011) 56
9.3.5 ConvaTec Inc., United Kingdom, Category Revenue Share (2011) 58
9.3.6 ConvaTec Inc., Other Europe, Category Revenue Share (2011) 60
9.4 ConvaTec Inc., Middle East and Africa, Category Revenue Share (2011) 62
9.5 ConvaTec Inc., North America, Category Revenue Share (2011) 64
9.5.1 ConvaTec Inc., Canada, Category Revenue Share (2011) 66
9.5.2 ConvaTec Inc., United States, Category Revenue Share (2011) 68
9.6 ConvaTec Inc., South and Central America, Category Revenue Share (2011) 70
9.6.1 ConvaTec Inc., Brazil, Category Revenue Share (2011) 72
9.6.2 ConvaTec Inc., Other South and Central America, Category Revenue Share (2011) 74
10 Key Employees 76
11 Key Employee Biographies 77
12 Locations And Subsidiaries 78
12.1 Head Office 78
12.2 Other Locations & Subsidiaries 78
13 Financial Deals Landscape 81
13.1 ConvaTec Inc., Deals Volume Summary, 2006 to YTD 2012 81
14 ConvaTec Inc., Deals Summary By Region, 2006 to YTD 2012 82
15 ConvaTec Inc. Detailed Deal Summary 84
15.1 Private Equity 84
15.1.1 Carlyle Acquires ConvaTec 84
15.1.2 Nordic Capital Fund And Avista Capital Partners Acquire ConvaTec From Bristol-Myers Squibb 85
15.2 Partnerships 87
15.2.1 ConvaTec Enters Into An Agreement With HemCon Medical Technologies 87
15.2.2 ConvaTec Enters Into An Agreement With Boehringer Wound Systems 88
15.2.3 ConvaTec Completes Private Placement Of 10.5% Senior Unsecured Notes For $750 Million 89
15.2.4 ConvaTec Completes Private Placement Of 10.875% Senior Unsecured Notes For $335 Million 90
15.2.5 ConvaTec Completes Private Placement Of 7.375% Senior Secured Notes For $403 Million 91
15.3 Asset Transactions 92
15.3.1 ConvaTec Sells Unomedical Wound Care And Ophthalmics Business To Aspen Surgical Products 92
15.4 Acquisition 93
15.4.1 ConvaTec Completes Acquisition Of 180 Medical, Intermittent Catheters Provider, From Cortec Group For $321 Million 93
15.4.2 ConvaTec Acquires AbViser Medical, Maker Of Disposable Monitoring Devices 95
15.4.3 ConvaTec Acquires Boston Medical Device 96
15.4.4 ConvaTec Acquires Unomedical Holding 97
16 Recent Developments 98
16.1 Strategy And Business Planning 98
16.1.1 Dec 14, 2012: ConvaTec Launches Operations In India 98
16.1.2 Feb 02, 2009: ConvaTec Plans To Expand In Greensboro 98
16.1.3 Nov 12, 2007: Alltracel Signs Development Agreement With ConvaTec 98
16.2 Financial Announcements 99
16.2.1 Nov 29, 2012: ConvaTec Healthcare Reports Revenue Of $406.3m In Q3 2012 99
16.2.2 Aug 29, 2012: ConvaTec Healthcare Reports Revenue Of $403.7m In Q2 2012 101
16.2.3 May 30, 2012: ConvaTec Healthcare Reports Revenue Of $371.1m In Q1 2012 101
16.2.4 Apr 19, 2012: ConvaTec Healthcare Reports Revenue Of $1.6 Billion In 2011 103
16.2.5 Nov 15, 2011: ConvaTec Healthcare Reports Revenue Of $411.3m In Q3 2011 104
16.2.6 Aug 23, 2011: ConvaTec Healthcare Reports Revenue Of $386.9m In Q2 2011 105
16.2.7 Jun 17, 2011: ConvaTec Healthcare Reports Revenue Of $362m In Q1 2011 106
16.2.8 Apr 28, 2011: ConvaTec Healthcare Reports Revenue Of $1.5 Billion In 2010 107
16.3 Research And Development 107
16.3.1 Apr 15, 2011: ConvaTec New In Vitro Study Data Show That Wound Dressing With Silver Kills MRSA And Other Superbugs Resistant To Antibiotics 107
16.4 Corporate Communications 108
16.4.1 Apr 26, 2012: ConvaTec Appoints Edward Borkowski As CFO 108
16.4.2 Feb 21, 2012: ConvaTec Appoints Ken Berger As New CEO 108
16.4.3 Aug 17, 2011: ConvaTec Announces Management Appointments 109
16.4.4 Jul 15, 2011: Convatec Appoints Robbie Heginbotham To Leadership Team 109
16.4.5 Feb 25, 2011: ConvaTec Appoints Adrienne McNally As Senior Vice President And Chief Quality Officer 109
16.4.6 Feb 07, 2011: ConvaTec Announces New Appointments 110
16.4.7 Nov 09, 2010: ConvaTec Appoints Bradford Barton As President Of ConvaTec US 110
16.4.8 Apr 05, 2010: US National Guideline Clearinghouse Re-Accepts Solutions Algorithms From ConvaTec 110
16.4.9 Mar 24, 2009: ConvaTec Appoints Stephan Becker As General Manager Of DACH Region 111
16.4.10 Mar 23, 2009: ConvaTec Appoints President, Continence And Critical Care Business Unit, EMEA Region 111
16.4.11 Oct 29, 2008: ConvaTec Appoints Presidents For Wound Therapeutics And Ostomy Care Business Units 112
16.5 Legal and Regulatory 113
16.5.1 Dec 19, 2012: ConvaTec Prevails In Patent Case Brought By Smith & Nephew 113
16.5.2 Dec 18, 2008: KCI Files Patent Violation Lawsuit Against Convatec and Boehringer 113
16.6 Government and Public Interest 113
16.6.1 Jul 14, 2010: Convatec Supports Development Of Guidelines For Appropriate Use Of NPWT In Spectrum Of Wound Healing 113
16.7 Product News 114
16.7.1 Dec 17, 2012: ConvaTec Announces New Use Of Aquacel Foam Dressing To Protect Against Skin Breakdown Caused By Friction And Moisture 114
16.7.2 Oct 01, 2012: Study Finds 78% Drop In Surgical Site Infection With ConvaTec’s Aquacel Ag Surgical Cover Dressing 115
16.7.3 Sep 12, 2012: ConvaTec Launches Aquacel Ag Burn Dressing With Hydrofiber Technology At ISBI 115
16.7.4 Sep 12, 2012: ConvaTec Launches Aquacel Burn With Hydrofiber Technology At ISBI 116
16.7.5 Jun 12, 2012: ConvaTec Launches Enhanced Flexi-Seal SIGNAL FMS 117
16.7.6 Jun 11, 2012: ConvaTec Introduces AQUACEL Foam Dressing At 44th Annual WOCN In Charlotte, North Carolina 118
16.7.7 Jun 11, 2012: ConvaTec Presents Clinical Results Of Moldable Technology Skin Barriers At 44th Annual Conference Of WOCN Society 118
16.7.8 May 23, 2012: ConvaTec Introduces AQUACEL EXTRA Wound Dressings With Hydrofiber Technology In Europe 119
16.7.9 Feb 13, 2012: ConvaTec Introduces AQUACEL EXTRA Wound Dressings With Hydrofiber Technology In US 120
16.7.10 Feb 09, 2012: ConvaTec Introduces AQUACEL Ag Burn Dressing With Hydrofiber Technology For Management Of Partial Thickness Burns 121
16.7.11 Sep 28, 2011: ConvaTec’s Vitala Pouchless Continence Control Device Shown To Be Safe And Effective For Up To 12 Hours In Phase III Clinical Trial 121
16.7.12 Jun 23, 2011: Preliminary Results Of Large Scale Study Show ConvaTec Moldable Technology Skin Barriers Help To Prevent And Improve Peristomal Skin Issues In Ostomy Patients 122
16.7.13 Jun 16, 2011: Studies Demonstrate Safety, Efficacy And Benefits Of Vitala Pouchless Continence Control Device 123
16.7.14 Jun 06, 2011: Convatec Introduces Thinner Versiva XC Dressing Designed To Improve Conformability 124
16.7.15 Nov 30, 2010: ConvaTec Reports Positive Phase II Clinical Study Results Of Vitala Continence Control Device 124
16.7.16 Nov 18, 2010: ConvaTec Receives UK Product Award For Flexi-Seal FMS 125
16.7.17 Sep 24, 2010: ConvaTec Announces Laboratory Data Analyzing Physical Performance Characteristics Of Bio-Dome And GranuFoam Negative Pressure Wound Therapy Dressings 126
16.7.18 Sep 02, 2010: ConvaTec Introduces AQUACEL And AQUACEL Ag Ribbon Dressings 126
16.7.19 Aug 24, 2010: ConvaTec Receives CE Mark Approval For Vitala Continence Control Device 127
16.7.20 Jun 14, 2010: ConvaTec Presents Phase II Trial Data Supporting Safety And Efficacy Of Vitala Continence Control Device 127
16.7.21 Jun 10, 2010: ConvaTec Receives Medical Design Excellence Gold Award For Vitala Continence Control Device 128
16.7.22 Apr 19, 2010: ConvaTec Wins 2010 Medical Design Excellence Award For Vitala Continence Control Device 129
16.7.23 Apr 18, 2010: ConvaTec Announces In Vitro Study Results Of Hydrofiber Dressing 129
16.7.24 Apr 18, 2010: ConvaTec Announces Study Results Demonstrating Budget Impact Of Flexi-Seal FMS In Hospital ICU 130
16.7.25 Apr 09, 2010: ConvaTec Receives FDA 510(K) Approval For Vitala Continence Control Device 131
16.7.26 Mar 31, 2010: ConvaTec Launches AQUACEL Ag SURGICAL Cover Dressings With Hydrofiber Technology 132
16.7.27 Feb 22, 2010: ConvaTec Launches Flexi-Seal SIGNAL FMS 133
16.7.28 Aug 24, 2009: ConvaTec Announces Data On Safety Of AQUACEL Ag Dressing For Use In MRI Environment 133
16.7.29 May 28, 2009: ConvaTec’s Moldable Skin Barrier Shows High Levels Of Satisfaction In A Prospective Evaluation 134
16.7.30 May 14, 2009: ConvaTec Introduces New AQUACEL Ag Dressing With Strengthening Fiber 135
16.7.31 Jan 22, 2009: ConvaTec Receives Expanded Indications For AQUACEL And AQUACEL Ag Dressings 135
16.7.32 Oct 28, 2008: ConvaTec Announces Launch Of Sur-Fit Natura Low-Pressure Adaptor 136
16.7.33 Oct 20, 2008: Convatec Introduces Flexi-Seal FMS Advanced Odor Control 137
16.7.34 May 14, 2008: ConvaTec Introduces VERSIVA XC Gelling Foam Dressings To US 137
16.7.35 May 02, 2008: ConvaTec Upgrades Flexi-Seal Fecal Management System To Increase Ease Of Use 137
16.8 Product Approvals 138
16.8.1 Aug 24, 2010: ConvaTec Receives CE Mark Approval For Vitala Continence Control Device 138
16.8.2 Jan 22, 2009: ConvaTec Receives Expanded Indications For AQUACEL And AQUACEL Ag Dressings 138
16.9 Clinical Trials 139
16.9.1 Oct 01, 2012: Study Finds 78% Drop In Surgical Site Infection With ConvaTec’s Aquacel Ag Surgical Cover Dressing 139
16.9.2 Jun 11, 2012: ConvaTec Presents Clinical Results Of Moldable Technology Skin Barriers At 44th Annual Conference Of WOCN Society 140
16.9.3 Sep 28, 2011: ConvaTec’s Vitala Pouchless Continence Control Device Shown To Be Safe And Effective For Up To 12 Hours In Phase III Clinical Trial 141
16.9.4 Jun 23, 2011: Preliminary Results Of Large Scale Study Show ConvaTec Moldable Technology Skin Barriers Help To Prevent And Improve Peristomal Skin Issues In Ostomy Patients 142
16.9.5 Jun 16, 2011: Studies Demonstrate Safety, Efficacy And Benefits Of Vitala Pouchless Continence Control Device 143
16.9.6 Nov 30, 2010: ConvaTec Reports Positive Phase II Clinical Study Results Of Vitala Continence Control Device 144
16.9.7 Jun 14, 2010: ConvaTec Presents Phase II Trial Data Supporting Safety And Efficacy Of Vitala Continence Control Device 144
16.9.8 Apr 18, 2010: ConvaTec Announces In Vitro Study Results Of Hydrofiber Dressing 145
16.9.9 Aug 24, 2009: ConvaTec Announces Data On Safety Of AQUACEL Ag Dressing For Use In MRI Environment 146
16.9.10 May 28, 2009: ConvaTec’s Moldable Skin Barrier Shows High Levels Of Satisfaction In A Prospective Evaluation 146
16.10 Other Significant Developments 147
16.10.1 Apr 23, 2012: Convatec Donates $10,000 To AAWC Global Volunteers Program Through SAWC Walk For Wellness 147
16.10.2 Jun 07, 2011: ConvaTec Presents New Data On ConvaTec Moldable Technology And Vitala Continence Control Device In Ostomy Care 148
16.10.3 Apr 18, 2011: Convatec Donates $10,000 To AAWC Global Volunteers Program Through SAWC Walk For Wellness 148
16.10.4 Apr 13, 2011: ConvaTec To Present Supported Studies At 24th Annual Symposium On SAWC/WHS In Dallas, Texas 149
16.10.5 Feb 25, 2011: ConvaTec Launches Campaign To Reduce Risk Of Pressure Ulcers Using 1-2-3 Strategy At National Pressure Ulcer Advisory Panel 12th Biennial Conference 150
16.10.6 Jan 18, 2011: Hospitals, Healthcare Providers To Benefit From New Premier Agreements For Enterostomal Therapy Products 151
16.10.7 Apr 05, 2010: US National Guideline Clearinghouse Re-Accepts Solutions Algorithms From ConvaTec 151
16.10.8 Jan 19, 2010: ConvaTec Donates Medical Supplies To Aid Haiti Relief Efforts 151
17 Appendix 153
17.1 Research Methodology 154
17.2 Secondary Research 154
17.3 Primary Research 154
17.4 Models 155
17.5 Forecasts 155
17.6 Expert Panels 155
17.7 GlobalData Consulting 155
17.8 Currency Conversion 156
17.9 Contact Us 157
17.10 Disclaimer 157
【レポート販売概要】
■ タイトル：ConvaTec Inc.：市場シェア分析■ 英文：ConvaTec Inc. Market Share Analysis
■ 発行日：2013年2月28日
■ 調査会社：GlobalData
■ 商品コード：GDATA403160485
■ 調査対象地域：グローバル
- ドキュメント解析の世界市場予測（～2024年）Growing initiatives to digitalize content across enterprises expected to drive the growth of the document analysis market The global document analysis market size is expected to grow from an estimated value of USD 438 million in 2019 to USD 3,855 million by 2024, at a CAGR of 54.5% during the forecast period. The document analysis industry is driven by various factors, such as growing initiatives …
- 先端エネルギー貯蔵システムの世界市場分析：技術別（電池、フライホイール、熱、圧搾空気、溶融塩）、セグメント予測 2022Global Advanced Energy Storage Systems Market By Technology (Batteries, Flywheel, Thermal, Compressed Air, Molten Salt) Is Expected To Reach USD 6.93 Billion By 2022May 2015 Global advanced energy storage systems market is expected to reach USD 6.93 billion by 2022. Increasing demand for utility scale power generation particularly during peak hours is expected to augment demand for advanced energy …
- 中国の石炭産業分析：Analyzing the Coal Industry in ChinaChina is the third biggest country of coal resources in the world and its annual coal output and consumption rank number one in the world. Coal industry is the basic industry in China and it plays an important role in the construction of the Chinese economy and the development of the society. The Chinese coal industry has kept good development trends in recent years. The coal market is in great in …
- 動物用寄生虫薬のグローバル市場動向（～2018）The veterinary pharmaceuticals including parasiticides have transformed the health of companion and livestock animals across the globe in the past two decades. Today, the spectrum of parasiticides for the veterinary applications continues to expand with variety of ectoparasiticides, endoparasiticides, and endectocides being launched every year. The innovations are leading to emergence of novel par …
- パッケージ化された廃水処理設備の世界市場2016-2020About Packaged Wastewater Treatment Packaged wastewater treatment plants are pre-engineered and custom designed treatment facilities used to treat wastewater for small communities, municipalities, and industries. These plants are typically constructed in a factory and simply transported to and installed at the site of requirement. They are designed to treat 0.002- 5 MGD water, depending on the req …
- 非小細胞肺癌：世界市場（医薬品市場予測及び分析～2022）PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer in men and women. Historically, the treatment paradigm has centered around chemotherapy. However, the launch of targeted therapies for patients with specific biomarkers has begun to fragment the NSCLC …
- 小売産業におけるパーソナライゼーショントレンド（事例分析）Summary “Trends in Personalization in Retail” report, published by Conlumino, gives a snapshot of some of the current examples of personalization in retail and the issues that arise. Key Findings - Retailers are utilizing a host of platforms, including mobile and social media to engage customers and offer them a personalized shopping experience. - 3D printing is gaining traction as a means to offe …
- サイトメガロウイルス(CMV)治療の世界市場2019-2023About this market High prevalence of congenital CMV will drive the CMV therapeutics market growth in the forthcoming years. Vendors are increasingly conducting researches to launch novel therapeutics including vaccines that can be administered in newborns. This will also prevent the progression of CMV while catering to the huge unmet need in the market. As a result, the high prevalence of congenit …
- ヒトメタニューモウイルス（hMPV）ワクチンの世界市場機会分析Human metapneumovirus (hMPV) is a member of the Metapneumovirus genus in the Pneumovirinae subfamily of the Paramyxoviridae family. The virus is transmitted between humans via direct or close contact and has a seasonality of infection similar to influenza and RSV. hMPV is the second most common cause of lower respiratory tract infections after RSV in young children. Most common causes for hospital …
- 世界の量子ドット市場（製品、応用分野、材料、地域別予測と分析）This report refers to the QD technology market, which caters to awide range of applications, products, and materials. QD technology products cover QD film, QD display, , QD panels, QD solar cells, and QD laser; QD technology-based application areas cover biotechnology, biological, clinical, defence, computing, solar, optoelectronics, and security. QD technology based materials cover cadmium seleni …
- Colbun S.A.：発電所及びSWOT分析2013Colbun S.A. - Power Plants and SWOT Analysis, 2013 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executives), and major products and services. Scope - Major Power Plants (assets) - summarized and detaile …
- ピラティス用品の世界市場2016-2020About Pilates Equipment The Pilates equipment markets in developed countries such as the US, Germany, the UK, Japan, and Australia have relatively high penetration rates, and are nearing saturation. Much of the growth over the forecast period is expected from developing nations, which have considerable growth opportunities in the sports and fitness equipment market in general. The Pilates equipmen …
- 血液分析装置・試薬の世界市場2015-2019About Hematology Analyzers and Reagents Hematology instruments are indispensable diagnostic tools and continue to sustain a strong position in the Global Healthcare industry. They include analyzers, flow cytometers, coagulation analyzers, and slide strainers. Hematology analyzers are computerized and highly specialized machines that determine the presence, count, and types of cellular elements in …
- 消費者信用の世界市場2016-2020About Consumer Credit Consumer credit, also known as consumer debt, refers to debt incurred by individual customers during the purchase of goods or services. Consumer credit includes purchases that are made with lines of credit, credit cards, and loans. Basically, there are two kinds of consumer credit. These are revolving line of credit and non-revolving line of credit, which is also known as ins …
- PharmaFocus: HIV – R&D Strategies towards Cure and PreventionPharmaFocus: HIV - R&D Strategies towards Cure and Prevention Summary It has been 30 years since the discovery that HIV is the causative agent of AIDS, and yet no preventative vaccine or cure that allows independence from lifelong antiretroviral treatment exists. Despite some recent setbacks, such as the discontinuation of the HVTN 505 clinical trial due to a trend of increased infection, there ha …
